In a mid-stage study of 34 patients, 33 were cured of the virus after 24 weeks of treatment with AbbVie’s experimental cocktail of ombitasvir, ritonavir, dasabuvir, ABT-450,
and ribavirin, an antiviral drug used to supplement
hepatitis C treatments. The study was published today in the New England Journal of Medicine.
Liver transplant patients are particularly in need of new hepatitis C treatments with better cure rates and fewer side effects.